Search results for " transplantation."

showing 10 items of 1389 documents

Related versus unrelated donor transplantation for high risk (HiRi) acute myeloid leukemia (AML) in first complete remission (CR1)

2007

Abstract Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-identical sibling donor (SIB) is considered the preferred postremission therapy for younger patients with HiRi AML in CR1. The role of allo-SCT from volunteer unrelated donors (VUDs) is less clear and randomized controlled trials addressing this issue do not exist. We performed an observational landmark analysis on parallel cohorts of patients aged <60 years with AML in CR1 and HiRi cytogenetics who had been enrolled into the AML Cooperative Group (AMLCG) 1999 trial. 2347 patients were evaluable for the present update. 243/2347 patients were <60 years of age and had unfavorable cytogenetics [com…

Oncologymedicine.medical_specialtybusiness.industrySurrogate endpointmedicine.medical_treatmentImmunologyMyeloid leukemiaCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrylaw.inventionLog-rank testTransplantationRandomized controlled triallawhemic and lymphatic diseasesInternal medicineImmunologymedicineObservational studySiblingbusiness
researchProduct

Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive A…

2015

Abstract Background: Activating mutations in receptor tyrosine kinases like FLT3 (FLT3mut) lead to an aberrant signal transduction thereby causing an increased proliferation of hematopoietic cells. Internal tandem duplications (FLT3-ITD) or mutations in the tyrosine kinase domain (FLT3-TKD) occur in about 25% of younger adult patients (pts) with acute myeloid leukemia (AML), with FLT3 -ITD being associated with an unfavourable outcome. FLT3mut present an excellent target for small molecule tyrosine kinase inhibitors (TKI). The multi-targeted kinase inhibitor midostaurin (PKC412) is currently under investigation as a FLT3-inhibitor in combination with intensive chemotherapy. Monitoring of th…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistryChemotherapy regimenTargeted therapychemistry.chemical_compoundchemistryMaintenance therapyInternal medicinePharmacodynamicsmedicineCytarabineMidostaurinbusinessNeoadjuvant therapymedicine.drugBlood
researchProduct

Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors.

2020

Oncologymedicine.medical_specialtymTORiPatient risk2720 HematologyMEDLINE610 Medicine & healthStratification (mathematics)Internal medicinemedicineHumansEverolimusSirolimusEverolimusHematologybusiness.industry10031 Clinic for AngiologyTOR Serine-Threonine KinasesAnticoagulantsHematologyVenous ThromboembolismDiscovery and development of mTOR inhibitorsKidney TransplantationTransplantationRenal transplantSirolimusbusinessImmunosuppressive AgentsVenous thromboembolismmedicine.drugThrombosis research
researchProduct

The road map toward an hepatitis C virus-free transplant population

2018

Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the posttransplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pretransplant patients with advanced liver disease. Earlier intervention, either before transplantation or early after LT, is now feasible with the advent of second-generation direct-acting antiviral agents (DAAs) with superior t…

Oncologymedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusinfectious diseasePopulationHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeclinical research/practiceinfection and infectious agents—viral: hepatitis CAntiviral Agents03 medical and health sciencesLiver diseasePostoperative Complications0302 clinical medicineeditorial/personal viewpointInternal medicinemedicineHumansImmunology and Allergyliver disease: infectiousPharmacology (medical)educationclinical research/practice; editorial/personal viewpoint; infection and infectious agents—viral: hepatitis C; infectious disease; liver disease: infectious; liver transplantation/hepatology; Immunology and Allergy; Transplantation; Pharmacology (medical)education.field_of_studyTransplantationbusiness.industrymedicine.diseaseHepatitis CLiver TransplantationTransplantationClinical trialhepatitis C infectious disease liver disease: infectious liver transplantation/hepatology [clinical research/practice editorial/personal viewpoint infection and infectious agents-viral]TolerabilityHepatocellular carcinoma030211 gastroenterology & hepatologybusinessliver transplantation/hepatology
researchProduct

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review

2021

Patients with postransplant lymphoproliferative disease (PTLD) who are refractory to rituximab-based regimens have extremely poor prognosis. Data is lacking in the setting of solid organ transplantation (SOT)-related PTLD treated with chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, limited information is available on the influence of concomitant immunosuppressive drugs on CAR-T function. Here, we describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion. This report also reviews the limited published data in the setting of SOT-related PTLD treated…

Oncologymedicine.medical_specialtymedicine.medical_treatmentImmunotherapy AdoptiveGeneral Biochemistry Genetics and Molecular BiologyRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansKidneyReceptors Chimeric Antigenbusiness.industryImmunosuppressionOrgan TransplantationGeneral MedicineLymphoproliferative DisordersTransplant RecipientsChimeric antigen receptorDiscontinuationsurgical procedures operativemedicine.anatomical_structureConcomitantRituximabLymphoproliferative diseasebusinessmedicine.drugCurrent Research in Translational Medicine
researchProduct

Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study

2012

Item does not contain fulltext INTRODUCTION: A recent genome-wide association study in European systemic sclerosis (SSc) patients identified three loci (PSORS1C1, TNIP1 and RHOB) as novel genetic risk factors for the disease. The aim of this study was to replicate the previously mentioned findings in a large multicentre independent SSc cohort of Caucasian ancestry. METHODS: 4389 SSc patients and 7611 healthy controls from different European countries and the USA were included in the study. Six single nucleotide polymorphisms (SNP): rs342070, rs13021401 (RHOB), rs2233287, rs4958881, rs3792783 (TNIP1) and rs3130573 (PSORS1C1) were analysed. Overall significance was calculated by pooled analys…

Oncologymedicine.medical_specialtysystemic sclerosisRHOBImmunologyGenome-wide association studySingle-nucleotide polymorphismBioinformaticsPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyArticleWhite PeopleRheumatologyRisk FactorsInternal medicineRhoB GTP-Binding Proteinsystemic sclerosis; genome wide screening; genetic risk factorsmedicinegenetic risk factorsImmunology and AllergySNPHumansGenetic Predisposition to DiseaseAllelerhoB GTP-Binding ProteinRheumatology and AutoimmunityScleroderma Systemicbusiness.industryHaplotypeProteinsgenome wide screeningDNA-Binding ProteinsEuropeHaplotypesCohortEvaluation of complex medical interventions Auto-immunity transplantation and immunotherapy [NCEBP 2]businessGenome-Wide Association Study
researchProduct

Association between sleep-disordered breathing and periodontitis: a meta-analysis

2022

Systemic inflammation is a feature of sleep-disordered breathing (SDB) as well as periodontitis. The association between SDB and periodontitis, however, has been inconsistent in previous studies. In order to fully evaluate the above association, we conducted a meta-analysis. Observational studies related to the aim of the meta-analysis were identified by search of PubMed, Embase, Web of Science, Wanfang, and CNKI databases. Only studies with SDB diagnosed with the objective polysomnography examination were included. The results were analyzed using a random-effects model that incorporated potential heterogeneity between studies. Ten cross-sectional or case-control studies with 43,296 partici…

Otorhinolaryngology2014 national institutes of health consensus criteriaSurgeryhematopoietic cell transplantationoral chronic graft-versus-host diseaseGeneral Dentistryoral mucosal diseaseUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Les membranes en chirurgie pré-implantaire

2012

The use of membranes in pre-implantation surgery is part of the guided bone regeneration (GBR) concept, one of the usual bone augmentation techniques. Membranes for GBR procedures have two main uses: a mechanical function to maintain bone regeneration space and a physical function as cellular barrier. The goal is to promote colonization of the regeneration space located under the membrane, by osteogenic cells from the residual bone walls. GBR was the subject of numerous publications and protocols since its first use in the 1980s. These protocols are mainly supported by team experience and the level of evidence is poor. Few indications are truly validated. The goal of our study was to review…

OtorhinolaryngologyBone transplantationbusiness.industryRegeneration (biology)DentistryMedicineSurgeryOral SurgeryPhysical functionbusinessBone regenerationRational useBone augmentationRevue de Stomatologie et de Chirurgie Maxillo-faciale
researchProduct

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

2021

Abstract Background Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). Methods This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. Results We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range,…

PNEUMONIAMalevirusesmedicine.medical_treatmentseasonal human coronavirusHematopoietic stem cell transplantationmedicine.disease_causeDISEASElaw.inventionCoronavirus OC43 HumanCLINICAL CHARACTERISTICSlawCoronavirus 229E HumanRisk FactorsImmunology and AllergyChildRespiratory Tract InfectionsNL63 INFECTIONSCoronavirusOUTCOMESRespiratory tract infectionsSYNCYTIAL VIRUSHazard ratioHematopoietic Stem Cell Transplantationvirus diseasesupper and lower respiratory tract diseaseHCoV-NL63HCoV-229Erespiratory systemMiddle AgedIntensive care unitHospitalizationimmunocompromisedsurgical procedures operativeInfectious Diseasesmedicine.anatomical_structureAcademicSubjects/MED00290Child PreschoolCohortFemaleSeasonsCoronavirus InfectionsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; immunocompromised; immunodeficiency score index; multiplex PCR assay; seasonal human coronavirus; upper and lower respiratory tract diseaseAdultmedicine.medical_specialtyHCoV-OC43AdolescentDIAGNOSISCHINAHCoV-HKU1BetacoronavirusAll institutes and research themes of the Radboud University Medical Centerstomatognathic systemInternal medicinemedicineMajor ArticleRHINOVIRUSHumansallogeneic hematopoietic stem cell transplantationAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryInfantmultiplex PCR assayTransplantationCoronavirus NL63 HumanPARAINFLUENZA VIRUSbusinessimmunodeficiency score indexRespiratory tract
researchProduct

Comparison between Rapid Intraoperative and Central Laboratory Parathormone Dosage in 12 Kidney Transplant Candidates

2016

Abstract Background The rapid intraoperative parathormone (PTH) and at central laboratory PTH dosage gives similar results. The central laboratory provides results in longer times and higher costs. Intraoperative measurement can reduce time and costs during parathyroidectomy. Methods Twelve patients undergoing parathyroidectomy for hyperparathyroidism renal transplant candidates were included. Diagnosis was made by laboratory tests (serum calcium, PTH) and imaging techniques (ultrasonography and scintigraphy). All patients presented PTH levels of >400 pg/mL (the limit value to be maintained in list for kidney transplantation) and resistant to medical therapy. For each patient, 2 blood sampl…

ParathyroidectomyAdultMalemedicine.medical_specialtyWaiting Listsmedicine.medical_treatmentOperative TimeParathyroid hormoneScintigraphyKidney transplantCentral laboratory03 medical and health sciences0302 clinical medicineMonitoring IntraoperativemedicineHumansKidney transplantationParathyroidectomyHyperparathyroidismTransplantationmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseKidney TransplantationSurgery; TransplantationSurgerySettore MED/18 - Chirurgia GeneraleParathyroid Hormone030220 oncology & carcinogenesisAnesthesiaKidney Failure Chronic030211 gastroenterology & hepatologySecondary hyperparathyroidismFemaleHyperparathyroidism SecondarySurgerybusiness
researchProduct